SFO
RLMD icon

Stokes Family Office’s Relmada Therapeutics RLMD Stock Holding History

Stokes Family Office’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,935
Closed -$220K – 292
2022
Q3 		$220K Buy
+5,935
New +$164K 0.03% 244

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stokes Family Office's RLMD Position: Q4 2022 in Review

Stokes Family Office sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 5,935 shares — an estimated $220K sold.

Stokes Family Office first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $220K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Stokes Family Office reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Stokes Family Office sold 5,935 Relmada Therapeutics shares in Q4 2022, an estimated $220K.
  • Stokes Family Office first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
  • Stokes Family Office's Relmada Therapeutics position peaked at $220K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Stokes Family Office's 13F filing for Q4 2022, filed 14 Feb 2023.